Leaders in industry and science met and discussed recent advances in cell and gene therapy research and development at an industry-focused event held on Thursday, June 28, 2018, at the Meyrick Hotel in Galway, Ireland. Industry representation included presentations from Takeda, ReNeuron, Avectas and Valitacell. ADIPOA-2 Coordinator PI Prof Frank Barry presented the project’s mission, progress and innovative aspects.
The emerging fields of cell and gene therapy are considered by many to be the next revolution in medicine, promising unprecedented and previously unimaginable treatments for major life-altering conditions and degenerative diseases. There are few areas of biomedical research which have attracted so much attention in recent years and been surrounded by so much expectation and promise. However, serious challenges remain in addressing manufacturing efficiency, cost reduction, clinical trials and delivery to patients.
The event sponsors were The Celtic Advanced Life Science Innovation Network, an Ireland Wales 2014-2020 programme partially funded by the European Regional Development Fund through the Welsh Government.
Speakers included: Robin Ali, University College London, Frank Barry REMEDI at NUI Galway, John Sinden, ReNeuron, Michael McGuire Avectas, Andrew Finnerty CCMI, Maria del Pilar Redondo, Takeda Europe, Mary Murphy REMEDI at NUI Galway, Stephanie Davis Valitacell and Gerry McCauliffe of Omnispirant.
Read the entire event programme: CALIN Galway Programme.